Publication

Preliminary results from an ongoing phase 2, open-label, multicenter, single-arm study assessing an every-4-week dosing schedule of mogamulizumab in patients with cutaneous t-cell lymphoma

Scarisbrick, J.
; 
Querfeld, C.
; 
Akilov, O.
; 
Bagot, M.
; 
Córdoba, R.
; 
Cowan, Richard
; 
García-Sancho, A. M.
; 
Geskin, L. J.
; 
Huen, A. O.
; 
Jadwani, J.
... show 10 more
Citations
Altmetric:
Abstract
Authors
Scarisbrick, J.
Querfeld, C.
Akilov, O.
Bagot, M.
Córdoba, R.
Cowan, Richard
García-Sancho, A. M.
Geskin, L. J.
Huen, A. O.
Jadwani, J.
Liu, Y.
Zhao, H.
Morris, S.
Ortiz-Romero, P. L.
Patel, A.
Pinter-Brown, L. C.
Pujol, R. M.
Quaglino, P.
Saba, N. S.
Vuppugalla, R.
Kim, Y. H.
Affiliation
Christie Hospital Foundation NHS Trust, University of Manchester, Manchester, United Kingdom
Description
Date
2024
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Scarisbrick J, Querfeld C, Akilov O, Bagot M, Córdoba R, Cowan R, et al. Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing an Every-4-Week Dosing Schedule of Mogamulizumab in Patients with Cutaneous T-Cell Lymphoma. EUROPEAN JOURNAL OF CANCER. 2024 OCT;211:S30-S1. PubMed PMID: WOS:001330761900064. English.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/627377
Embedded videos